ONWARDS 4 compared once-weekly insulin icodec with once-daily insulin glargine, both in combination with mealtime insulin. The objective of the trial was to assess the efficacy and safety of insulin icodec in people with type 2 diabetes treated with basal and bolus insulin. In this touchENDOCRINOLOGY interview, Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) gives us a brief overview of the ONWARDS clinical trial programme as well as the objectives and the findings of the ONWARDS 4 clinical trial.
The abstract entitled: ‘Once-Weekly Insulin Icodec vs Once-Daily Insulin Glargine U100 in Combination with Bolus Insulin in Individuals with Type 2 Diabetes on Basal-Bolus Regimens (ONWARDS 4)‘ was presented at the 22nd Annual Diabetes Technology Meeting, 03-05 Nov, 2022.
Questions:
- Could you give us a brief overview of the ONWARDS clinical trial programme? (0:20)
- What were the objectives of the ONWARDS 4 study? (2:15)
- What was the primary endpoint and how well was it achieved? (3:43)
- What is the safety and tolerability findings of the study? (5:22)
Disclosures: Chantal Mathieu has received grant/research support from Medtronic, Imcyse, Novo Nordisk, Sanofi and ActoBio Therapeutics.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of DTM 2022
